Immunovia has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc.
Jeff Borcherding will be part of the Immunovia group management team from April 11.
“I’m very pleased that Jeff Borcherding will join Immunovia. Jeff’s appointment further accelerates the US commercialization efforts of IMMray PanCan-d and is in-line with our strategic priority to scale our US business. Immunovia commercially entered the US, the world’s largest diagnostics market, with the launch of IMMray PanCan-d in August 2021. Jeff brings extensive experience growing diagnostic businesses and healthcare brands from a broad range of commercial leadership roles in the US market. Immunovia is fully focused on making the IMMray PanCan-d test broadly available in the US,” says Philipp Mathieu, Acting CEO and President, Immunovia AB.
Jeff joins Immunovia from Myriad Genetics, where he most recently served as Chief Marketing Officer. Previously, Jeff was the general manager for Myriad’s mental health business unit, leading dramatic growth of Myriad’s GeneSight test. Jeff is a former Procter & Gamble brand manager, where he successfully grew multiple healthcare brands. He has held several commercial leadership roles at health care and software companies. Jeff is a graduate of Indiana University with a B.S. in business and earned an MBA from the Kellogg Graduate School of Management at Northwestern University.
“Pancreatic cancer is a horrific disease, and we need better ways to detect it at an early stage. Immunovia has developed the first diagnostic test to do this, which is a tremendous achievement and gives us an incredible opportunity to help people at risk for pancreatic cancer. I’m very excited to be part of the Immunovia team for this once-in-a-lifetime journey,” says Jeff Borcherding.